A nucleic acid-based multi-gene panel test of tumour tissue from a patient with cholangiocarcinoma requested by, or on behalf of, a specialist or consultant physician, if the test is to: (a) detect at least IDH1 variant status, and (b) detect the fusion or rearrangement status of at least FGFR2; and (c) determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme including a service described in item 73319. Applicable once per lifetime.
A nucleic acid-based multi-gene panel test of tumour tissue from a patient with cholangiocarcinoma requested by, or on behalf of, a specialist or consultant physician, if the test is to: (a) detect at least IDH1 variant status, and (b) detect the fusion or rearrangement status of at least FGFR2; and (c) determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme including a service described in item 73319. Applicable once per lifetime.
| Release | Change | Old | New |
|---|---|---|---|
| July 2026 | Listed | — | $800.0 |
Data sourced from Australian Government publications · Not an official government service